|Bid||10.84 x 800|
|Ask||10.87 x 800|
|Day's Range||10.39 - 10.88|
|52 Week Range||9.90 - 29.10|
|Beta (3Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
Investors are always looking for growth in small-cap stocks like Flexion Therapeutics, Inc. (NASDAQ:FLXN), with a market cap of US$389m. However, an important fact which most ignore is: how financially healthy is the business...
The Compensation Committee of the Board of Directors approved the grants with an effective date of April 1, 2019. The stock options and restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $12.42 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.
BURLINGTON, Mass., April 03, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will.
Flexion Therapeutics, Inc. (FLXN) today announced an independent evaluation of clinical data for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), conducted by Adis Drug Review, was published in the journal Drugs (Vol 79 (4) pp 455–462). The evidence-based evaluation concluded that ZILRETTA provided effective pain relief, while being generally well-tolerated as demonstrated in clinical studies, and it expands the treatment options for osteoarthritis (OA) knee pain.
Flexion Therapeutics today announced that Kerry Wentworth, Chief Regulatory Officer, has been appointed to the Massachusetts Biotechnology Council (MassBio) Board of Directors. “It is a pleasure to welcome Kerry to our Board of Directors,” said Robert K. Coughlin, President and CEO of MassBio.
Mutual fund managers like Eaton Vance's Bill Bell, Baron's Randy Gwirtzman and Parnassus' Lori Keith have an upbeat stock market forecast for the near term. "We're 10 years into the bull market," said Bell, co-manager of $410 million Eaton Vance Atlanta Capital Select Equity Fund (ESEIX).
BURLINGTON, Mass., March 04, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will present at.
QUEBEC CITY , March 4, 2019 /CNW Telbec/ - Opsens Inc. ("Opsens") (OPS.TO) (OPSSF) is pleased to announce the appointment of Mr. Alan Milinazzo as Executive Chairman of the Board of Directors. "We are delighted to see Alan, a renowned leader in the medical device industry, join us. Alan has had extensive success in building high-performance commercial teams in interventional cardiology.
Company reported net ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) sales of $22.5 million for full-year 2018Since launch, 90% of target accounts.
BURLINGTON, Mass., Feb. 26, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 40th Annual Raymond James Institutional Investors.
Flexion Therapeutics, Inc. (FLXN) today announced results from a preclinical study which showed that triamcinolone acetonide (TA) had protective effects on inflamed and/or injured cartilage. Led by Professor Alan Grodzinsky, Sc.D., Director of the Center for Biomedical Engineering at the Massachusetts Institute of Technology (MIT), the study utilized an established in vitro model1 with cartilage explants subjected to inflammatory cytokines and a single impact mechanical injury.
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion Therapeutics, Inc. (FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Thursday, February 28, 2019. The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #2570919. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and a Top Place to Work in Massachusetts by The Boston Globe.
Flexion Therapeutics, Inc. (FLXN) today announced that the results from an open-label Phase 3b clinical trial evaluating the safety and exploratory efficacy of repeat administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with osteoarthritis (OA) of the knee were published in Rheumatology and Therapy. The data indicate that repeat administration of ZILRETTA was generally safe and well-tolerated.
Flexion Therapeutics, Inc. (FLXN) announced today that it has been invited to ring the Nasdaq opening bell on Tuesday, February 12, 2019 to commemorate the fifth anniversary of the company’s initial public offering (IPO). Michael Clayman, M.D., President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's trading session. “Ringing the Nasdaq opening bell on the fifth anniversary of our IPO serves as a poignant reminder of just how much Flexion has grown and evolved over the past five years,” said Dr. Clayman.
NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Flexion Therapeutics, Inc. (FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009, and she most recently served as the company’s Senior Vice President of Program Management and Strategy. In her expanded role, Ms. Willwerth will continue to lead the planning and execution of the company’s strategic vision and priorities, and she has accountability for Flexion’s portfolio development efforts and Human Resources activities.
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks reached 52-week highs Thursday. Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. ...